Vol. 2 No. 12 (2022)
Reimbursement Recommendations

Guselkumab (Tremfya)

Published December 5, 2022

Key Messages

  • CADTH recommends that Tremfya be reimbursed by public drug plans for the treatment of active psoriatic arthritis (PsA) if certain conditions are met.
  • Tremfya should only be reimbursed to treat adult patients with active PsA according to the reimbursement criteria used for other biologic disease-modifying antirheumatic drugs (DMARDs) that are currently reimbursed by public drug plans.
  • Tremfya should only be reimbursed if it is prescribed by a rheumatologist or a clinician who has experience treating adult patients with active PsA and if it does not cost more than other biologic DMARDs or targeted synthetic DMARDs. Tremfya should not be reimbursed when used together with other biologic or targeted synthetic DMARDs for active PsA.